International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.7947330
Original Article
To Study the Efficacy of Oral Gabapentin for Attenuation of the Hemodynamic Response to Direct Laryngoscopy and Tracheal Intubation
 ,
 ,
Published
May 18, 2023
Abstract
Introduction: Since the inception of general anesthesia it has been well recognized that laryngoscopy & tracheal intubation is a noxious stimulus, which is associated with hemodynamic changes in the form of increase in blood pressure & heart rate [1, 2 & 3]. We conducted a prospective, randomised, double‑blind, clinical trial to examine whether a single preoperative dose of 800 mg oral gabapentin would be effective in blunting the hemodynamic response to laryngoscopy & tracheal intubation. Aims and Objectives: The main objective of the study is to see the effect of administering oral Gabapentin 800 mg on direct laryngoscopy & tracheal intubation. The secondary objective is to study any side effect of oral dose of 800 mg of Gabapentin like, Dizziness, Somnolence, Nausea, Vomiting and others. Methods: After obtaining institutional ethical clearance, study was conducted for 2 years from October 2020 to October 2022 at tertiary care center.60 patients of either sex (18–50 years of age) undergoing elective surgeries under general anesthesia were randomly allocated to two groups of 30 patients each. Patients of Group A received oral gabapentin 800 mg 2 hr before anticipated intubation, while patients in Group B received oral placebo at the same time. Results: Patients receiving gabapentin 800 mg showed remarkable decrease in HR, MAP, SBP and DBP in response to tracheal intubation (P < 0.05) compared to placebo group.None of the patient has suffered from any side‑effects. Conclusion: Oral Gabapentin 800 mg is efficacious and safe in blunting the hemodynamic response to laryngoscopy and tracheal intubation.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
946 Views
165 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved